|1.||Ibrahim, Nuhad K: 3 articles (01/2013 - 02/2003)|
|2.||Miles, David: 3 articles (01/2013 - 02/2003)|
|3.||Mitchell, Malcolm S: 3 articles (11/2003 - 01/2002)|
|4.||Parker, Joanne: 2 articles (01/2011 - 10/2005)|
|5.||Murray, James Lee: 2 articles (01/2011 - 02/2003)|
|6.||Holmberg, Leona A: 2 articles (12/2004 - 02/2003)|
|7.||Sandmaier, Brenda M: 2 articles (12/2004 - 02/2003)|
|8.||Longenecker, B M: 2 articles (11/2001 - 06/2000)|
|9.||Sandmaier, B M: 2 articles (09/2001 - 06/2000)|
|10.||Holmberg, L A: 2 articles (09/2001 - 06/2000)|
|1.||Breast Neoplasms (Breast Cancer)
02/01/2003 - "More than 1000 breast cancer patients with metastatic disease are currently enrolled in a phase III clinical trial to assess the safety and efficacy of the STn-KLH vaccine. "
01/01/2002 - "Phase II trials suggest prolongation of survival of advanced breast cancer patients who generate high titers of antibody to Theratope. "
08/01/2000 - "A multinational phase III study testing the Theratope vaccine in patients with metastatic breast cancer who have had a clinical response or stability of disease is ongoing. "
01/01/2013 - "Adding STn-KLH to endocrine therapy may improve clinical outcomes with few adverse effects for women with metastatic breast cancer."
01/01/2003 - "In June 2002, Biomira stated that it believes the market size for THERATOPE in the US, Europe and Japan to be approximately 184000 patients for the indication of metastatic breast cancer, of which the US would be 100000, Europe 75000 and Japan 9000. "
12/01/2004 - "The cancer vaccine Theratope was developed by Biomira, Inc. "
01/01/2003 - "Biomira is developing a therapeutic cancer vaccine [THERATOPE] for treatment of breast and other cancers. "
01/01/2003 - "Cancer vaccine THERATOPE- Biomira."
11/01/2001 - "When LN cells were injected subcutaneously in the presence of STn-KLH-sensitized lymphocytes, tumor growth was decreased. "
09/01/2001 - "Theratope vaccine is a cancer vaccine that was designed by Biomira, Inc. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
02/01/2003 - "Between 1995 and 2000, 70 patients (16 with stage II/III breast cancer, 17 with stage III/IV ovarian cancer, and 37 with stage IV breast cancer) were treated with 2 different formulations of STn-KLH. "
02/01/2003 - "The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope)."
01/01/2003 - "THERATOPE consists of the mucin antigen, sialyl-Tn (STn), a carbohydrate located on the surface of breast, colorectal and ovarian cancer cells, conjugated to keyhole limpet haemocyanin (KLH). "
06/01/2000 - "We conclude that the THERATOPE STn-KLH cancer vaccine is well tolerated in breast and ovarian cancer patients after autologous transplant and, while not statistically significant, the trends in data support the concept that THERATOPE vaccine may decrease the risk for relapse and death and thus warrants further study. "
06/01/2000 - "Forty patients (11 high-risk stage II/III breast cancer, 22 stage IV breast cancer, and seven stage III/IV ovarian cancer patients) were treated with high-dose chemotherapy followed by autologous/syngeneic stem cell rescue and vaccination with THERATOPE STn-KLH (Sialyl-Tn-KLH with Detox-B Stable Emulsion). "
|4.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2003 - "For the indication of colorectal cancer, the total market population for THERATOPE is expected to be 183000 patients, of which the US has been estimated at 100000, Europe 75000 and Japan 9000."
01/01/1996 - "Breast and colorectal cancer patients who had the highest anti-OSM antibody titers, determined 4 weeks after the fourth immunization with STn-KLH (post-4 ASI), survived longer than the patients who had lower post-4 active specific immunotherapy (ASI) anti-OSM antibody titers. "
09/01/1995 - "Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients."
01/01/1996 - "The humoral immune response of 85 metastatic breast, ovarian, and colorectal cancer patients was analyzed after immunization with THERATOPE STn-KLH (KLH, keyhole limpet hemocyanin) cancer vaccine emulsified in DETOX adjuvant. "
01/01/2011 - "injection of 100 μg STn-KLH plus adjuvant (treatment group) or 100 μg KLH plus adjuvant (control group) at weeks 0, 2, 5, and 9. Subsequently, STn-KLH without adjuvant or KLH without adjuvant was then administered monthly for 4 months, and then quarterly until disease progression, without cyclophosphamide. "
|1.||sialyl-Tn antigen-keyhole-limpet hemocyanin conjugate
|7.||keyhole-limpet hemocyanin (keyhole limpet hemocyanin)
|3.||Drug Therapy (Chemotherapy)
|4.||Stem Cell Transplantation
|5.||Combination Drug Therapy (Combination Chemotherapy)